VYNE Q1 continuing ops loss $8.7M; divested MST franchise for $25M; positive FMX114 Phase 1b data

VYNE Therapeutics Inc.

2022-Q1 EPS reported $0.08 revenue$178,000

Q1 2022 GAAP loss from continuing ops $8.7M ($7.4M adjusted); net income $4.7M reflecting divestiture gain.
Divested MST franchise (AMZEEQ, ZILXI) to Journey Medical for $25M upfront plus up to $450M milestones.
FMX114 Phase 1b showed stat sig reduction in ADSI score vs vehicle; Phase 2a topline expected Q2 2022.
VYN201 preclinical data demonstrated efficacy in rheumatoid arthritis and vitiligo models vs active controls.
Entered $30M equity purchase agreement with Lincoln Park Capital over 36 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.